ciglitazone has been researched along with Diabetes Mellitus, Type 1 in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mishra, PK | 1 |
| Tyagi, N | 1 |
| Sen, U | 1 |
| Joshua, IG | 1 |
| Tyagi, SC | 1 |
1 other study available for ciglitazone and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.
Topics: Animals; Antioxidants; Cardiomyopathies; Cyclic N-Oxides; Diabetes Complications; Diabetes Mellitus, | 2010 |